Navigation Links
At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
Date:4/15/2008

Neurochem Annual and Special Meeting web cast live

LAVAL, QC, April 15 /PRNewswire-FirstCall/ - At the Annual and Special meeting of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), shareholders will be asked to officially adopt the Company's new name, BELLUS Health Inc., which it expects to start using on April 21, 2008, together with the new stock ticker symbols (NASDAQ: BLUS; TSX: BLU). Neurochem will also present the launch activities that are in preparation for VIVIMIND(TM), the first branded natural health product to be marketed by its new, wholly owned, nutraceutical subsidiary, OVOS Natural Health Inc., to protect memory function. Shareholders will also learn that Neurochem has regained full ownership rights and control on eprodisate (KIACTA(TM)) from Centocor Inc., a wholly owned subsidiairy of Johnson and Johnson, for the prevention and treatment of Amyloid A (AA) amyloidosis.

"Fiscal 2007 was a difficult year for Neurochem, but we have risen to the challenge by adopting an expanded corporate strategy to assure revenue generation in the short-term through the sale of natural health products and long-term development of a rich product pipeline in pharmaceuticals," said Dr. Francesco Bellini, Neurochem's Chairman, President and Chief Executive Officer. "Our name-change to BELLUS Health will reflect the broader scope of our activities, while the creation of our subsidiary, OVOS Natural Health, as well as the imminent launch of VIVIMIND(TM) for memory protection, testify to our determination to mo
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
2. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
3. Northwest Hospital & Medical Center Hosts Health & Wellness Pavilion At Second Annual King 5 Healthy Living Expo
4. European Society of Human Reproduction & Embryology 24th annual meeting
5. Media advisory - Neurochems Annual and Special Meeting of Shareholders April 15, 2008
6. Neurochem Annual and Special Meeting of shareholders
7. With annual deaths from malaria on the rise: Scientists ask where is all the money going?
8. China Medical Technologies to Announce 4QFY2007 Financial Results, Declare Annual Cash Dividend and Provide FY2008 Annual Targets on June 12, 2008
9. HealthMEDX Hosts Annual User Group Conference
10. Abaxis to Present at the SunTrust Robinson Humphreys 37th Annual Institutional Unconference
11. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...s embracing the latest tools of virtual communicat...ue with patients. Through Facebook, Twitter, and o...formation about his Atlanta plastic surgery prac...ts may have. , Atlanta, G...in Atlanta is taking full advantage of new online...
(Date:11/24/2009)...ser Clinic, located in San Diego, is helping the f... new modeling career. The race to remove his chest...n the middle of 2010 is on. , ...aser Clinic, located in San Diego, is helping the ...s new modeling career. The race to remove his ches...
(Date:11/23/2009)... team of researchers at the University of Californ...d a way to simulate blood flow on the computer to ...w tool that may help surgeons plan for a life-savi... performed on babies born with severe congenital h...eir work next week at the 62nd Annual Meeting of t...
(Date:11/23/2009)...upusFoundationofAmericaGreaterWashingtonChapter(LF...to-dayeducation,adviceandresourcesforthe75,000+peo...FAGW,s35thAnniversaryLuncheonwillbeheldonSat.,Dece...ettsAve.,N.E.,Washington( map ).Dress:Businessatti...oropportunitiesare$1,500including10seats,tableandp...
(Date:11/23/2009)...CMG)EncouragesFamiliestoGatherFamilyHealthHistoryI...009 ,, BETHESDA,Md.,Nov.23/PRNewswire-USNewswi...yHistoryDay,asdeclaredbytheU.S.SurgeonGeneral.TheA...ryonetoknowtheirfamilymedicalhistoryandiftheyhaven...tion,to"starttheconversation"aboutfamilymedicalhis...
Breaking Medicine News(10 mins):Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 2Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 3Health News:Tattoo Removal on the Fastest U.S. Marine 2Health News:New tool for helping pediatric heart surgery 2Health News:Washington Lupus Chapter Celebrates 35th Anniversary on December 5 2Health News:'Family Health History and Genetics Privacy' is the Newest Addition to the ACMG Genetics & Your Health Video Series 2
... drugs approved for use as second line therapy for...g results as frontline therapy for newly diagnosed...ed by scientists at The University of Texas M. D. ...enetic response - absence of the aberrant chromoso...
...on Health & Science University Cancer Institute re...of chronic myeloid leukemia (CML). , We are looki...here the cancer is coming from. We have discovere...t of the CML clone, said Thomas Bumm, M.D., OHSU C...
...oing to the doctor or overindulge in unhealthy hab...hDay News) -- The holiday season is also the seaso...hurchwell, associate director of the Vanderbilt He...ion deaths occurring between 1973 and 2001 reveals...
...December 8, 2007 -- Results from two investigation...nation with bortezomib provide preliminary anti-tu...actory multiple myeloma. Data from one study show... second study, sponsored by the United States Nati...
... Data that shed new light on,the treatment of resi...al,hip replacement, chronic immune thrombocytopeni...stmenopausal hormone replacement therapy will,be p..., December 8, from 10:00 to 11:00 a.m., "Complica...
...L, December 8, 2007 A series of studies presented...acology (ACNP) annual meeting elucidates evidence ... and cancer, providing a surprising possible scien... , Researchers at the National Institute for Me...
Other Medicine News:Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 2Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 3Health News:OHSU Cancer Institute research discovery opens new window to understanding chronic myeloid leukemia 2Health News:Heart Attacks Peak During the Holidays 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 2Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 3Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 4Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 5Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 6Health News:Studies elucidate genetic links between cancer and schizophrenia 2
(Date:11/23/2009)...onewtherapiesforNon-Hodgkin,sLymphomas(NHL),theNCC...b(Azerra(TM),GlaxoSmithKline)asatherapyoptionforpa...psin(Istodax(R),GloucesterPharmaceuticals)asasugge...a(CTCL). ,, FORTWASHINGTON,Pa.,Nov.23/PRNewswir...eNationalComprehensiveCancerNetwork( NCCN )toupdat...
(Date:11/23/2009)...Reportlinker.comannouncesthatanewmarketresearchrep...Systems&Equipment-AGlobalMarketPerspective ,...zation-Systems--Equipment---A-Global-Market-Perspe...&utm_campaign=prnewswire ,, Steamsteril...rocedure.Steamsterilizationmarketisstableduetoregu...
(Date:11/23/2009)...Reportlinker.comannouncesthatanewmarketresearchrep...enDisposables-AWorldwideMarketReview ,, http...Disposables---A-Worldwide-Market-Review.html#utm_s...n=prnewswire ,, Withincreaseinrangeofinfect...eandhospitalfacilities,nonwovenshasemergedasagoldm...
Breaking Medicine Technology:NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 2Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 3Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 4Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 5Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 6Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective 7Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 2Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 3Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 4Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 5Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 6Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 7Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 8BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 1BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 3BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 4BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 5Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 1Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 1Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 3Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 4Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 5Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 7Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 8
...Med, the Hutchison Whampoa backed pharmaceutical a...lts for its Phase II,proof-of-concept study for HM...orm of inflammatory bowel disease. The trial met,...and showed an,equivalent drop in clinical symptom ...ent first-line standard of care in,mild-to-moderat...
...- Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a ...sease and dermatology, today announced that,resear... Paul,Janmey and Dr. Robert Bucki, in collaboratio...ity, have demonstrated in a series,of in vitro exp...wn,as CSA-13 shows promise as a potential therapy ...
Other Medicine Technology:Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 2Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 3Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 4Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 5Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 6Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 7Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 8Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections 2Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections 3Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections 4
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
Medicine Products: